IQVIA (NYSE:IQV) Price Target Cut to $210.00 by Analysts at Mizuho

IQVIA (NYSE:IQV) had its target price reduced by Mizuho from $242.00 to $210.00 in a report released on Wednesday,Benzinga reports. Mizuho currently has an outperform rating on the medical research company’s stock.

IQV has been the topic of several other research reports. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Stephens began coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. Barclays decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Six equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $241.50.

IQVIA Trading Down 9.9 %

Shares of NYSE IQV traded down $15.49 during trading on Wednesday, hitting $141.53. 1,223,945 shares of the company were exchanged, compared to its average volume of 1,363,512. The company has a fifty day moving average price of $184.54 and a 200-day moving average price of $200.91. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market capitalization of $24.95 billion, a PE ratio of 18.91, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA has a 12-month low of $135.97 and a 12-month high of $252.88.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts expect that IQVIA will post 10.84 EPS for the current year.

Institutional Trading of IQVIA

Several institutional investors have recently modified their holdings of the stock. Smith Group Asset Management LLC acquired a new position in IQVIA in the fourth quarter valued at $1,616,000. Nordea Investment Management AB grew its stake in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. acquired a new position in IQVIA during the fourth quarter worth approximately $941,000. Fifth Third Bancorp lifted its stake in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after buying an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS boosted its holdings in shares of IQVIA by 22.0% in the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after acquiring an additional 2,700 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.